<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327111434949</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327111434949</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of cytotoxicity of a new hemostatic agent Ankaferd Blood Stopper<sup>®</sup> using different assays</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mihmanli</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111434949">1</xref>
<xref ref-type="corresp" rid="corresp1-0960327111434949"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ulker</surname>
<given-names>Z</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327111434949">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alpsoy</surname>
<given-names>L</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327111434949">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ezirganli</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111434949">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0960327111434949">
<label>1</label>Faculty of Dentistry, Bezmialem Vakif University, Istanbul, Turkey</aff>
<aff id="aff2-0960327111434949">
<label>2</label>Department of Biology, Fatih University, Istanbul, Turkey</aff>
<author-notes>
<corresp id="corresp1-0960327111434949">Ahmet Mihmanli, Faculty of Dentistry, Bezmialem Vakif University, Fatih 34093, Istanbul, Turkey Email: <email>amihmanli@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>31</volume>
<issue>8</issue>
<fpage>780</fpage>
<lpage>787</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The aim of this study is to investigate the effects of the Ankaferd Blood Stopper<sup>®</sup> (ABS), on cell viability, cytotoxicity, and erythrocyte numbers in in vitro cultured human blood cells. We studied the cytotoxic effects of the ABS using lactate dehydrogenase (LDH) assay, cell proliferation (WST-1) assay and hemolytic assay. The cytotoxicity increased when cells were treated with ABS dilutions of 5%, 12.5%, 25%, and 50% (<italic>p</italic> &lt; 0.05). Moreover, treatment of the cells with the same concentrations significantly elevated the cell number at 24 and 48 h (<italic>p</italic> &lt; 0.05). ABS causes a significant increase (<italic>p</italic> &lt; 0.05) in the hemolytic activity on human erythrocytes and hemolytic activity increases with increase in ABS concentrations. The red blood cell aggregation and cell membrane disruption during the coagulation process lead to induction of hemolytic activity and increase of LDH level in cell culture medium. In addition, ABS has proliferative effects on human leukocytes. Based on these results, ABS can be used as an alternative blood stopping agent safely.</p>
</abstract>
<kwd-group>
<kwd>Ankaferd Blood Stopper<sup>®</sup> (ABS)</kwd>
<kwd>cytotoxicity</kwd>
<kwd>cell proliferation</kwd>
<kwd>hemolytic effects</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327111434949">
<title>Introduction</title>
<p>Ankaferd Blood Stopper<sup>®</sup> (ABS) is a unique folkloric medicinal plant extract. The basic principle of ABS is the formation of an encapsulated protein network providing focal points for vital erythrocytes to aggregate on. The ABS-induced protein network formation involves blood cells, particularly erythrocytes, aggregation but does not affect the physiological individual coagulation systems.<sup><xref ref-type="bibr" rid="bibr1-0960327111434949">1</xref></sup> ABS is a standardized mixture of the plants <italic>Thymus vulgaris</italic> (dried leaf), <italic>Glycyrrhiza glabra</italic> (dried leaf), <italic>Vitis vinifera</italic> (dried leaf), <italic>Alpinia officinarum</italic> (dried leaf), and <italic>Urtica dioica</italic> (dried root; <xref ref-type="table" rid="table1-0960327111434949">Table 1</xref>); each of these has some effects on the endothelium, blood cells, angiogenesis, cellular proliferation, vascular dynamics, and/or cell mediators.<sup><xref ref-type="bibr" rid="bibr1-0960327111434949">1</xref><xref ref-type="bibr" rid="bibr2-0960327111434949"/>–<xref ref-type="bibr" rid="bibr3-0960327111434949">3</xref></sup>
</p>
<table-wrap id="table1-0960327111434949" position="float">
<label>Table 1.</label>
<caption>
<p>Ingredients of ampoule of ABS</p>
</caption>
<graphic alternate-form-of="table1-0960327111434949" xlink:href="10.1177_0960327111434949-table1.tif"/>
<table>
<thead>
<tr>
<th>Name of active ingredient</th>
<th>Amount of active gradient (mg) in an ampoule (2 mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<italic>Urtica dioica</italic>
</td>
<td>0.12</td>
</tr>
<tr>
<td>
<italic>Vitis vinifera</italic>
</td>
<td>0.16</td>
</tr>
<tr>
<td>
<italic>Glycyrrhiza glabra</italic>
</td>
<td>0.18</td>
</tr>
<tr>
<td>
<italic>Alpinia officinarum</italic>
</td>
<td>0.14</td>
</tr>
<tr>
<td>
<italic>Thymus vulgaris</italic>
</td>
<td>0.10</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>
<italic>T. vulgaris</italic> has antispasmodic, carminative, diaphoretic, expectorant, and sedative properties. As a mixture, extract, or infusion, thyme is frequently used in throat and bronchial problems as well as for diarrhea, chronic gastritis, and loss of appetite.<sup><xref ref-type="bibr" rid="bibr4-0960327111434949">4</xref>,<xref ref-type="bibr" rid="bibr5-0960327111434949">5</xref>
</sup> <italic>G. glabra</italic> also has anti-inflammatory, antithrombin, antiplatelet, antioxidant, antiatherosclerotic, and antitumor activities.<sup><xref ref-type="bibr" rid="bibr1-0960327111434949">1</xref>,<xref ref-type="bibr" rid="bibr6-0960327111434949">6</xref>
</sup> <italic>V. vinifera</italic> seed extract in particular has been reported to possess a broad spectrum of pharmacological and therapeutic effects such as antioxidative, anti-infammatory, and antimicrobial activities as well as having cardioprotective, hepatoprotective, and neuroprotective effects.<sup><xref ref-type="bibr" rid="bibr7-0960327111434949">7</xref></sup> Ethnomedical uses for <italic>A. officinarum</italic> have been found against rheumatism, bronchial catarrh, bad breath, ulcers, whooping cough in children, throat infections, and to control incontinence.<sup><xref ref-type="bibr" rid="bibr8-0960327111434949">8</xref></sup> Finally, extracts of <italic>U. dioica</italic> have been reported to have an acute diuretic and hypotensive effects,<sup>
<xref ref-type="bibr" rid="bibr9-0960327111434949">9</xref>
</sup> cardiovascular effects,<sup><xref ref-type="bibr" rid="bibr10-0960327111434949">10</xref></sup> and can stimulate the proliferation of human lymphocyte.<sup><xref ref-type="bibr" rid="bibr11-0960327111434949">11</xref></sup>
</p>
<p>The ABS has dual diverse dynamic reversible actions on the endothelial protein C receptor (EPCR) and plasminogen activator inhibitor-1 (PAI-1), depending on the dose and concentration of EPCR and PAI-1 inside the vascular endothelial cells in the model of human umbilical vein endothelial cells (HUVECs) and have a role on numerous cellular functions as well as its hemostatic actions. Based on these findings, sudden antihemorrhagic efficacy of ABS has been attributed to its immediate enhancement of expression of prohemostatic PAI-1 and downregulated anticoagulant EPCR, resulting in the unique hemostatic effects of ABS. This mechanism could also be important to elucidate the effects of ABS in a given tissue.<sup><xref ref-type="bibr" rid="bibr12-0960327111434949">12</xref>,<xref ref-type="bibr" rid="bibr13-0960327111434949">13</xref></sup> Also, Ankaferd has ototoxic side effects and prolonged mass effects in rats.<sup><xref ref-type="bibr" rid="bibr14-0960327111434949">14</xref></sup>
</p>
<p>Crucial proteomic components of the ABS-induced erythroid-protein network have been revealed by Demiralp et al.<sup><xref ref-type="bibr" rid="bibr15-0960327111434949">15</xref></sup> Proteins of plant origin in Ankaferd are nicotinamide adenine dinucleotide phosphate (NADP)-dependent-malic enzyme, ribulose bisphosphatecarboxylase-large chain, maturase K, adenosine triphosphate (ATP) synthase subunit-β, ATP synthase subunit-α, chalcone-flavanone isomerase-1, chalcone-flavanone isomerase-2, and actin-depolymerizing factor. Functional proteomic studies revealed that proteins resembling human peptides within Ankaferd have detected 35 different proteins, including ATP synthase, dynactin 5, nicotinamide adenine dinucleotide (NADH) dehydrogenase (ubiquinone) 1-α-subcomplex, mitochondrial NADP(+)-dependent malic enzyme 3, and nuclear factor 1B-type.<sup><xref ref-type="bibr" rid="bibr16-0960327111434949">16</xref></sup>
</p>
<p>Ankaferd establishes a very fast and solid protein web and also alters the levels of transcription factors, such as activating protein 2 (AP2), androgen receptor (AR), cyclic AMP response element or activating transcription factor 1 (CRE-ATF1), cyclic AMP response element-binding protein (CREB), early growth response (E2F1-5, E2F6, EGR), globulin transcription factor (GATA), hepatocyte nuclear factor-1 (HNF1), interferon (IFN)-stimulated response element (ISRE), Myc-Max, nuclear factor-1 (NF1), nuclear factor kappa B (NF-Kb), protein 53 or tumor protein 53 (p53), peroxisome proliferator-activated receptor (PPAR), SMAD2/3, SP1, TPA response element/activating protein 1 (TRE/AP1), and Yin Yang 1 (YY1), in Human Umbilical Vein Endothelial Cells (HUVECs).<sup><xref ref-type="bibr" rid="bibr17-0960327111434949">17</xref></sup> In another study, Albayrak et al. reported that the addition of ABS into the serum of both multiple myeloma and the control groups resulted in significant decreases in the level of total protein, albumin, immunoglobulin G (IgG), IgA, and IgM.<sup><xref ref-type="bibr" rid="bibr18-0960327111434949">18</xref></sup>
</p>
<p>Furthermore, critical experiments are focusing on the effects of ABS in the vessels and tissues. ABS administered to experimental major arterial vessel injuries has reduced both bleeding time and blood loss under conditions of normal and elevated intra-arterial blood pressure. ABS-induced erythroid aggregation was prominent at the vascular tissue level.<sup><xref ref-type="bibr" rid="bibr19-0960327111434949">19</xref></sup> For most patients, 1 or 2 mL of ABS was enough for adequate control of bleeding during dental extractions and periodontal surgery.<sup><xref ref-type="bibr" rid="bibr20-0960327111434949">20</xref></sup> In the cases of severe hemorrhaging, ABS may act as a topical biological response modifier in the renal tubular cellular microenvironment. ABS induces downregulations in the expressions of apoptotic molecules.<sup><xref ref-type="bibr" rid="bibr21-0960327111434949">21</xref></sup>
</p>
<p>ABS has been safely used in patients to treat epistaxis,<sup>
<xref ref-type="bibr" rid="bibr22-0960327111434949">22</xref>,<xref ref-type="bibr" rid="bibr23-0960327111434949">23</xref>
</sup> after tonsillectomy,<sup><xref ref-type="bibr" rid="bibr24-0960327111434949">24</xref></sup> adenoidectomy,<sup><xref ref-type="bibr" rid="bibr25-0960327111434949">25</xref></sup> and total thyroidectomy<sup>
<xref ref-type="bibr" rid="bibr17-0960327111434949">17</xref></sup> or even variceal bleeding.<sup><xref ref-type="bibr" rid="bibr26-0960327111434949">26</xref></sup> In addition, ABS has been used to control upper gastrointestinal bleeding,<sup>
<xref ref-type="bibr" rid="bibr27-0960327111434949">27</xref>
</sup> life-threatening arterial bleeding of the digestive tract,<sup>
<xref ref-type="bibr" rid="bibr28-0960327111434949">28</xref>
</sup> and bleeding due to solitary rectal ulcer.<sup><xref ref-type="bibr" rid="bibr29-0960327111434949">29</xref></sup> Moreover, the levels of coagulation factors II, V, VIII, IX, X, XI, and XII were not affected by ABS; therefore, ABS might be used in patients with deficient primary hemostasis.<sup><xref ref-type="bibr" rid="bibr30-0960327111434949">30</xref></sup> The biological and toxicological properties of biomaterials are important for their clinical usage.<sup><xref ref-type="bibr" rid="bibr31-0960327111434949">31</xref></sup> In vitro cytotoxic screening as a primary factor of biocompatibility is determined by cell culture. The most appropriate cells (i.e. cells homologous to the human tissues of ultimate concern) should be selected for in vitro toxicity tests.<sup><xref ref-type="bibr" rid="bibr32-0960327111434949">32</xref></sup>
</p>
<p>The aim of this study was to evaluate the cytotoxicity of ABS using lactate dehydrogenase (LDH) assay, cell proliferation (WST-1) assay, and hemolytic assay.</p>
</sec>
<sec id="section2-0960327111434949" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0960327111434949" sec-type="materials">
<title>Materials</title>
<p>All products used for cell culture (Roswell Park Memorial Institute (RPMI), fetal bovine serum (FBS), Ficoll, <sc>l</sc>-glutamine, penicillin, and streptomycin) were purchased from Biochrom AG (Berlin, Germany) and Biological Industries (Kibbutz Beit-Haemek, Israel). WST-1, LDH, and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) kits were bought from Roche (Mannheim, Germany). Also ABS obtained from Trend Teknoloji Ilaç AS (Istanbul, Turkey).</p>
</sec>
<sec id="section4-0960327111434949">
<title>Isolation of PBMCs</title>
<p>The peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood samples by density gradient centrifugation with Ficoll. For LDH and WST-1 assays, PBMC samples were incubated in RPMI1640 medium with 2 mmol/L <sc>l</sc>-glutamine, 10% FBS, and antibiotics (penicillin and streptomycin) in the presence of 5% CO<sub>2</sub> at 37°C at 1.0 × 10<sup>6</sup> cells/mL<sup><xref ref-type="bibr" rid="bibr33-0960327111434949">33</xref></sup> with an ABS solution (1% (A1), 5% (A2), 12.5% (A3), 25% (A4), and 50% (A5)] for 24 and 48 h. All donors gave full written informed consent.</p>
</sec>
<sec id="section5-0960327111434949">
<title>LDH assay</title>
<p>A second set of cells were exposed to the test compounds for the LDH assay, which was performed using the LDH Cytotoxicity Detection Kit (Roche). For this assay, a positive control, leading to 100% cytotoxicity by lysing the cells completely, was included. The positive control was 2% Triton X-100 solution in the assay medium, as proposed by the manufacturer. After preincubation of the cells, but before the addition of the test compounds, the growth medium was exchanged from a medium containing 5% FBS to a medium containing only 1% FBS. For testing the released LDH activity, 100 μL of culture medium was transferred to a new 96-well plate at 24 and 48 h. Reaction solution of 100 μL was added from the kit, containing the detection dye, and the catalyst was then added and absorption was measured after 30 min at 490 nm with 655 nm as the reference wavelength in an enzyme-linked immunosorbent assay (ELISA) reader (BioTek-Power WaveS, USA). A culture medium without cells was used as a blank. As for the other assays, background values from wells without cells were subtracted and average value of the six times was calculated. Means ± SD values were represented in <xref ref-type="table" rid="table2-0960327111434949">Table 2</xref>. Cytotoxicity was then calculated according to the following equation
<disp-formula id="disp-formula1-0960327111434949">
<mml:math id="mml-disp1-0960327111434949">
<mml:mrow>
<mml:mtext>Cytotoxicity</mml:mtext><mml:mtext> </mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>%</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac>
<mml:mrow>
<mml:mrow><mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>experimental value</mml:mtext><mml:mo>−</mml:mo><mml:mtext>negative control</mml:mtext>
</mml:mrow>
<mml:mo>)</mml:mo></mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mrow><mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>positive control</mml:mtext><mml:mo>−</mml:mo><mml:mtext>negative control</mml:mtext>
</mml:mrow>
<mml:mo>)</mml:mo></mml:mrow>
</mml:mrow>
</mml:mfrac>
<mml:mn>100</mml:mn>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0960327111434949" xlink:href="10.1177_0960327111434949-eq1.tif"/>
</disp-formula>
</p>
<table-wrap id="table2-0960327111434949" position="float">
<label>Table 2.</label>
<caption>
<p>The cytotoxic effects of different concentrations of Ankaferd on human lymphocyte culture<sup><xref ref-type="table-fn" rid="table-fn1-0960327111434949">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table2-0960327111434949" xlink:href="10.1177_0960327111434949-table2.tif"/>
<table>
<thead>
<tr>
<th>Groups</th>
<th>24 h</th>
<th>48 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive control</td>
<td>1.96 ± 0.12</td>
<td>2.46 ± 0.09</td>
</tr>
<tr>
<td>Negative control</td>
<td>1.15 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref></sup>
</td>
<td>1.58 ± 0.54<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref></sup>
</td>
</tr>
<tr>
<td>Al</td>
<td>2.19 ± 0.33<sup><xref ref-type="table-fn" rid="table-fn3-0960327111434949">c</xref></sup>
</td>
<td>2.12 ± 0.12<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref></sup>
</td>
</tr>
<tr>
<td>A2</td>
<td>2.55 ± 0.04<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn3-0960327111434949">c</xref></sup>
</td>
<td>2.62 ± 0.10<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref>–<xref ref-type="table-fn" rid="table-fn4-0960327111434949">d</xref></sup>
</td>
</tr>
<tr>
<td>A3</td>
<td>2.28 ± 0.10<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn3-0960327111434949">c</xref>,<xref ref-type="table-fn" rid="table-fn5-0960327111434949">e</xref></sup>
</td>
<td>2.12 ± 0.20<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn5-0960327111434949">e</xref></sup>
</td>
</tr>
<tr>
<td>A4</td>
<td>1.98 ± 0.31<sup><xref ref-type="table-fn" rid="table-fn3-0960327111434949">c</xref>,<xref ref-type="table-fn" rid="table-fn6-0960327111434949">f</xref></sup>
</td>
<td>2.10 ± 0.06<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn5-0960327111434949">e</xref></sup>
</td>
</tr>
<tr>
<td>A5</td>
<td>1.05 ± 0.30<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn4-0960327111434949">d</xref>,<xref ref-type="table-fn" rid="table-fn6-0960327111434949">f</xref>–<xref ref-type="table-fn" rid="table-fn7-0960327111434949">g</xref></sup>
</td>
<td>1.43 ± 0.08<sup><xref ref-type="table-fn" rid="table-fn2-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn4-0960327111434949">d</xref>–<xref ref-type="table-fn" rid="table-fn7-0960327111434949">g</xref></sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327111434949">
<p>
<sup>a</sup>Ankaferd solutions of 1% (A1), 5% (A2), 12.5% (A3), 25% (A4), and 50% (A5).</p>
</fn>
<fn id="table-fn2-0960327111434949">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.05 when compared with positive control.</p>
</fn>
<fn id="table-fn3-0960327111434949">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.05 when compared with negative control.</p>
</fn>
<fn id="table-fn4-0960327111434949">
<p>
<sup>d</sup>
<italic>p</italic> &lt; 0.05 when compared with A1.</p>
</fn>
<fn id="table-fn5-0960327111434949">
<p>
<sup>e</sup>
<italic>p</italic> &lt; 0.05 when compared with A2.</p>
</fn>
<fn id="table-fn6-0960327111434949">
<p>
<sup>f</sup>
<italic>p</italic> &lt; 0.05 when compared with A3.</p>
</fn>
<fn id="table-fn7-0960327111434949">
<p>
<sup>g</sup>
<italic>p</italic> &lt; 0.05 when compared with A4.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-0960327111434949">
<title>Cell proliferation (WST-1) assay</title>
<p>For WST-1 assay, cells were cultured in the microplates (tissue culture grade, 96 wells, and flat bottom) with a final volume of 100 μL/well culture medium in a humidified atmosphere (37°C and 5% CO<sub>2</sub>). Cell proliferation reagent WST-1 was added in a 10-μL/well volume. Cells were incubated for 4 h in a humidified atmosphere (37°C and 5% CO<sub>2</sub>). The sample absorbances were measured at 420 nm with ELISA reader (BioTek-PowerWaveS, USA). Means ± SD values were represented in the <xref ref-type="table" rid="table3-0960327111434949">Table 3</xref>. Culture medium without cells was used as a blank.</p>
<table-wrap id="table3-0960327111434949" position="float">
<label>Table 3.</label>
<caption>
<p>The cell proliferation effects of different concentrations of Ankaferd on human lymphocyte culture<sup><xref ref-type="table-fn" rid="table-fn8-0960327111434949">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table3-0960327111434949" xlink:href="10.1177_0960327111434949-table3.tif"/>
<table>
<thead>
<tr>
<th>Groups</th>
<th>24 h</th>
<th>48 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>0.46 ± 0.08</td>
<td>0.53 ± 0.09</td>
</tr>
<tr>
<td>Al</td>
<td>1.63 ± 0.21<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref></sup>
</td>
<td>1.48 ± 0.28<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref></sup>
</td>
</tr>
<tr>
<td>A2</td>
<td>1.97 ± 0.14<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0960327111434949">c</xref></sup>
</td>
<td>1.89 ± 0.11<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0960327111434949">c</xref></sup>
</td>
</tr>
<tr>
<td>A3</td>
<td>1.90 ± 0.26<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref></sup>
</td>
<td>2.06 ± 0.14<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0960327111434949">c</xref></sup>
</td>
</tr>
<tr>
<td>A4</td>
<td>1.27 ± 0.40<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref>,<xref ref-type="table-fn" rid="table-fn11-0960327111434949">d</xref>,<xref ref-type="table-fn" rid="table-fn12-0960327111434949">e</xref></sup>
</td>
<td>0.97 ± 0.27<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref>–<xref ref-type="table-fn" rid="table-fn12-0960327111434949">e</xref></sup>
</td>
</tr>
<tr>
<td>A5</td>
<td>0.70 ± 0.16<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref>–<xref ref-type="table-fn" rid="table-fn13-0960327111434949">f</xref></sup>
</td>
<td>0.91 ± 0.09<sup><xref ref-type="table-fn" rid="table-fn9-0960327111434949">b</xref>–<xref ref-type="table-fn" rid="table-fn12-0960327111434949">e</xref></sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0960327111434949">
<p>
<sup>a</sup>Ankaferd solutions of 1% (A1), 5% (A2), 12.5% (A3), 25% (A4), and 50% (A5).</p>
</fn>
<fn id="table-fn9-0960327111434949">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.05 when compared with negative control.</p>
</fn>
<fn id="table-fn10-0960327111434949">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.05 when compared with A1.</p>
</fn>
<fn id="table-fn11-0960327111434949">
<p>
<sup>d</sup>
<italic>p</italic> &lt; 0.05 when compared with A2.</p>
</fn>
<fn id="table-fn12-0960327111434949">
<p>
<sup>e</sup>
<italic>p</italic> &lt; 0.05 when compared with A3.</p>
</fn>
<fn id="table-fn13-0960327111434949">
<p>
<sup>f</sup>
<italic>p</italic> &lt; 0.05 when compared with A4.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-0960327111434949">
<title>Hemolytic assay</title>
<p>Erythrocytes (red blood cells (RBCs)) were separated from plasma by centrifugation (400<italic>g</italic> at 10°C for 10 min) and washed twice with phosphate-buffered solution (PBS); then a first dilution (1:9) of erythrocytes in PBS at a final concentration of around 2.56 × 10<sup>8</sup> RBCs/mL was prepared. Cells were incubated for 15 min in 37°C and 5% CO<sub>2</sub>. After the incubation period, erythrocytes were separated by centrifugation (300<italic>g</italic> at 10°C for 10 min). A 200-mL portion of each supernatant was further transferred to a microwell plate to measure the absorbance at 405 nm into a microplate reader. Percentage hemolysis was calculated according to the following formula<disp-formula id="disp-formula2-0960327111434949">
<mml:math id="mml-disp2-0960327111434949">
<mml:mrow>
<mml:mtext>Hemolysis</mml:mtext><mml:mrow><mml:mo>(</mml:mo>
<mml:mi>%</mml:mi>
<mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac>
<mml:mrow>
<mml:mrow><mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>absorbance of sample</mml:mtext><mml:mo>−</mml:mo><mml:mtext>absorbance of blank</mml:mtext>
</mml:mrow>
<mml:mo>)</mml:mo></mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mrow><mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>highest absorbance for positive control</mml:mtext>
</mml:mrow>
<mml:mo>)</mml:mo></mml:mrow>
</mml:mrow>
</mml:mfrac>
<mml:mn>100</mml:mn>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0960327111434949" xlink:href="10.1177_0960327111434949-eq2.tif"/>
</disp-formula>
</p>
<p>Also the number of erythrocytes in the experimental groups was scored using hemacytometer.</p>
</sec>
<sec id="section8-0960327111434949">
<title>Statistical analysis</title>
<p>The statistical analysis of LDH and WST-1 data was performed using the Mann-Whitney <italic>U</italic> test. A value of <italic>p &lt;</italic> 0.05 was accepted as statistically significant. Results were expressed as mean ± SD. The statistical analysis of human erythrocyte number was evaluated using χ<sup>2</sup> test. For these procedures, SPSS 15.0 version for Windows (SPSS Inc, Chicago, Illinois, USA) was used.</p>
</sec>
</sec>
<sec id="section9-0960327111434949">
<title>Results</title>
<sec id="section10-0960327111434949">
<title>LDH assay results</title>
<p>The cytotoxic effects of different doses of ABS on human lymphocytes at 24 and 48 h are represented in <xref ref-type="table" rid="table2-0960327111434949">Table 2</xref> and <xref ref-type="fig" rid="fig1-0960327111434949">Figure 1</xref>. All the ABS concentrations except its 1% dilution caused the releasing LDH and cytotoxicity. Increases in the level of LDH were observed after treatment with 50%, 25%, 12.5%, and 5% dilutions of ABS when compared with negative control groups. This increase was found to be statistically significant (<italic>p</italic> &lt; 0.05). The highest cytotoxic effect of ABS was in the 25% dilution. As seen in the <xref ref-type="fig" rid="fig2-0960327111434949">Figure 2</xref>, when the ABS concentrations were increasing, the agglutination of lymphocyte was observed.</p>
<fig id="fig1-0960327111434949" position="float">
<label>Figure 1.</label>
<caption>
<p>The cytotoxic effects of different concentrations of Ankaferd on human lymphocyte culture. NC: negative control; A1: 1% Ankaferd solution; A2: 5% Ankaferd solution; A3: 12.5% Ankaferd solution; A4: 25% Ankaferd solution; A5: 50% Ankaferd solution.</p>
</caption>
<graphic xlink:href="10.1177_0960327111434949-fig1.tif"/>
</fig>
<fig id="fig2-0960327111434949" position="float">
<label>Figure 2.</label>
<caption>
<p>View of comparison effects of different concentration of Ankaferd on human lymphocyte culture cells (×10 magnification). (a): negative control group; (b): 1% Ankaferd solution; (c): 5% Ankaferd solution; (d): 50% Ankaferd solution.</p>
</caption>
<graphic xlink:href="10.1177_0960327111434949-fig2.tif"/>
</fig>
</sec>
<sec id="section11-0960327111434949">
<title>Cell proliferation (WST-1) assay results</title>
<p>
<xref ref-type="table" rid="table3-0960327111434949">Table 3</xref> and <xref ref-type="fig" rid="fig3-0960327111434949">Figure 3</xref> represent the results of the cell viability part of the present study, including the WST-1 assay in the control and experimental groups. Increases in the cell proliferation was observed after treatment with different concentrations of ABS. Statistical analysis showed a significant difference in cell viability between all the treated groups and the control group at 24 and 48 h. WST-1 assay results show that the cell proliferation increased when cells were treated with different ABS concentrations at 24 and 48 h (<italic>p</italic> &lt; 0.05). ABS at a concentration of A5 (50%) significantly increased cell proliferation at all time points during the 24 and 48 h (<italic>p</italic> &lt; 0.05) in comparison with all the concentrations and control. LDH release significantly correlated with increased cell proliferation. ABS at concentrations of A1 (1%), A2 (5%), A3 (12.5%), and A4 (25%) significantly increased cell proliferation at all time points during 24 and 48 h (<italic>p</italic> &lt; 0.05) in comparison with control.</p>
<fig id="fig3-0960327111434949" position="float">
<label>Figure 3.</label>
<caption>
<p>The cell proliferation effects of different concentrations of Ankaferd on human lymphocyte culture. NC: negative control; A1: 1% Ankaferd solution; A2: 5% Ankaferd solution; A3: 12.5% Ankaferd solution; A4: 25% Ankaferd solution; A5: 50% Ankaferd solution.</p>
</caption>
<graphic xlink:href="10.1177_0960327111434949-fig3.tif"/>
</fig>
</sec>
<sec id="section12-0960327111434949">
<title>Hemolytic assay result</title>
<p>ABS cause the hemolytic activity on human erythrocytes (RBC) as seen in <xref ref-type="fig" rid="fig4-0960327111434949">Figures 4</xref> and <xref ref-type="fig" rid="fig5-0960327111434949">5</xref>. Such an increased was found to be statistically significant (<italic>p</italic> &lt; 0.05). On the other hand, the number of RBCs was reduced by all the ABS concentrations. Especially, in the 12.5%, 25%, and 50% dilutions of ABS, the number of erythrocytes was found to be very low.</p>
<fig id="fig4-0960327111434949" position="float">
<label>Figure 4.</label>
<caption>
<p>Hemolytic activities of different concentrations of Ankaferd on human red blood cells. NC: negative control; A1: 1% Ankaferd solution; A2: 5% Ankaferd solution; A3: 12.5% Ankaferd solution; A4: 5% Ankaferd solution; A5: 50% Ankaferd solution; a: <italic>p</italic> &lt; 0.05 when compared with negative control; b: <italic>p</italic> &lt; 0.05 when compared with A1; c: <italic>p</italic> &lt; 0.05 when compared with A2; d: <italic>p</italic> &lt; 0.05 when compared with A3; e: <italic>p</italic> &lt; 0.05 when compared with A4.</p>
</caption>
<graphic xlink:href="10.1177_0960327111434949-fig4.tif"/>
</fig>
<fig id="fig5-0960327111434949" position="float">
<label>Figure 5.</label>
<caption>
<p>The effects of different concentrations of Ankaferd on human red blood cell numbers. NC: negative control; A1: 1% Ankaferd solution; A2: 5% Ankaferd solution; A3: 12.5% Ankaferd solution; A4: 5% Ankaferd solution; A5: 50% Ankaferd solution; a: <italic>p</italic> &lt; 0.05 when compared with negative control; b: <italic>p</italic> &lt; 0.001 when compared with negative control; c: <italic>p</italic> &lt; 0.05 when compared with A1; d: <italic>p</italic> &lt; 0.001 when compared with A1; e: <italic>p</italic> &lt; 0.05 when compared with A2.</p>
</caption>
<graphic xlink:href="10.1177_0960327111434949-fig5.tif"/>
</fig>
</sec>
</sec>
<sec id="section13-0960327111434949">
<title>Discussion</title>
<p>Hemostatic failure, a serious problem encountered in dentistry, can cause excessive postoperative bleeding, delayed wound healing, and increased risk of infection. Currently used agents for hemostasis, like fibrinogen and plasma-derived blood coagulation factors, may carry the risk of transmission of viral infection and formation of clotting factor inhibitors. ABS may offer a convenient alternative during dental procedures. ABS might also be effective for the patients with hemophilia and/or other hemostatic defects during dental procedures as indicated in case reports later in this article.<sup><xref ref-type="bibr" rid="bibr34-0960327111434949">34</xref></sup>
</p>
<p>The ideal hemostatic agents also should be free of cytotoxicity, but the ability of hemostasis is more important; however, after hemostasis is achieved, unused hemostatic material should be eliminated, leaving as little hemostatic agent as possible in order to avoid postoperative complications.<sup><xref ref-type="bibr" rid="bibr35-0960327111434949">35</xref></sup>
</p>
<p>Odabas et al. studied that ABS was cytotoxic to human pulp fibroblasts by MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a yellow tetrazole) assay. The influence of cytotoxicity to human pulp fibroblasts depended on the concentration of ABS. The more diluted concentrations exhibited less cytotoxic characteristics when compared with the more concentrated forms.<sup><xref ref-type="bibr" rid="bibr36-0960327111434949">36</xref></sup>
</p>
<p>There is not any information about  the components of ABS, which could induce cell proliferation and agglutination. According to Aydın et al., ABS may have some plant proteins known as lectins that bind to the cell surface and cause agglutination. Some of these plant proteins, discovered many years ago, are phytohemaglutinins because they bind to RBCs and agglutinate them.<sup><xref ref-type="bibr" rid="bibr37-0960327111434949">37</xref></sup> Also lectins such as phytohemaglutinin, which is used as a mitogen, can induce cell proliferation. In addition, a lectin isolated from <italic>U. dioica</italic> is called <italic>U. dioica</italic> lectin, which has been found to stimulate the proliferation of human lymphocytes.<sup><xref ref-type="bibr" rid="bibr11-0960327111434949">11</xref></sup> On the contrary, Odabas et al.<sup>
<xref ref-type="bibr" rid="bibr36-0960327111434949">36</xref>
</sup> reported that ABS inhibited cell proliferation.</p>
<p>In this study, the cell membrane alteration and cell proliferation after ABS treatment on human lymphocyte were analyzed by LDH release assay and WST-1 assay. Released LDH can be a useful marker in the explanation of early cell membrane alteration.<sup><xref ref-type="bibr" rid="bibr38-0960327111434949">38</xref><xref ref-type="bibr" rid="bibr39-0960327111434949"/>–<xref ref-type="bibr" rid="bibr40-0960327111434949">40</xref></sup> Jurisic et al. reported that the release of LDH is significantly correlated with the decreased cell proliferation induced with 10,000 pg/mL tumor necrosis factor-α (TNF-α). However, TNF-α, at lower concentrations (125 and 250 pg/mL), increased cell proliferation, nonetheless LDH released in Raji cells.<sup><xref ref-type="bibr" rid="bibr41-0960327111434949">41</xref></sup>
</p>
<p>In our study, data indicated that an increase in spontaneous LDH release significantly correlated with increased cell proliferation induced with ABS. The maximal peak of LDH release and cell number were detected 24 h after ABS (25%) treatment. When human lymphocytes were treated with high concentrations of ABS, the agglutination increased (<xref ref-type="fig" rid="fig2-0960327111434949">Figure 2</xref>). Due to the proliferation of cells, LDH released from the cells to a culture medium increased. Also ABS reduced the number of cells and hemolytic activity because of cell agglutination on human erythrocytes.</p>
</sec>
<sec id="section14-0960327111434949">
<title>Conclusion</title>
<p>ABS is a herbal extract, and it has been used as a hemostatic agent in Anatolia for centuries. Although the exact mechanism of ABS still remains unknown, it is a well-known fact that plants such as ABS have certain impact on hemostatic system in various ways. For one thing, ABS might affect fibrinogen-like interactions between ABS and blood proteins as well as other proteins through the agglutination of these molecules, which are also driven by ABS itself. The presence of ABS is also effective in the aggregation of blood cells, particularly RBCs, and activated leukocytes at an increasing level. During the coagulation process, proteins and cells in blood agglutinate stop bleeding and therefore cell membrane of blood cells, particularly RBCs, get damaged by this agglutination. The results of our study revealed that cytotoxic and proliferative effects of ABS might shed light on this process outlined above.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327111434949">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327111434949">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goker</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Ercetin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kirazli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Akman</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Ozturk</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper</article-title>. <source>J Int Med Res</source> <year>2008; </year>
<volume>36</volume>: <fpage>163</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr2-0960327111434949">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Umano</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shibamoto</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Identification of volatile components in basil (<italic>Ocimum basilicum</italic> L.) and thyme leaves (<italic>Thymus vulgaris</italic> L.) and their antioxidant properties</article-title>. <source>Food Chem</source> <year>2005</year>; <volume>91</volume>: <fpage>131</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr3-0960327111434949">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salimath</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Sheela</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ramakrishna</surname>
<given-names>MK</given-names>
</name>
</person-group>. <article-title>Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibited by <italic>Glycyrrhiza glabra</italic>
</article-title>. <source>Inter Immunopharmacol</source> <year>2006</year>; <volume>6</volume>: <fpage>494</fpage>–<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr4-0960327111434949">
<label>4</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>S</given-names>
</name>
</person-group>. <source>Encyclopedia of common natural ingredients used in food</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>1996</year>, pp.<fpage>350</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr5-0960327111434949">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Behnia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haghighi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Komeylizadeh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tabaei</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Abadi</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Inhibitory effects of Iranian <italic>Thymus vulgaris</italic> extracts on in vitro growth of <italic>Entamoeba histolytica</italic>
</article-title>. <source>Korean J Parasitol</source> <year>2008</year>; <volume>46</volume>: <fpage>153</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr6-0960327111434949">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheela</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ramakrishna</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Salimath</surname>
<given-names>BP</given-names>
</name>
</person-group>. <article-title>Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibited by <italic>Glycyrrhiza glabra</italic>
</article-title>. <source>Int Immunopharmacol</source> <year>2006</year>; <volume>6</volume>: <fpage>494</fpage>–<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr7-0960327111434949">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nassiri-Asl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hosseinzadeh</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Review of the pharmacological effects of <italic>Vitis vinifera</italic> (grape) and its bioactive compounds</article-title>. <source>Phytother Res</source> <year>2009</year>; <volume>23</volume>: <fpage>1197</fpage>–<lpage>1204</lpage>.</citation>
</ref>
<ref id="bibr8-0960327111434949">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author"><name><surname>Srividya</surname><given-names>AR</given-names></name><name><surname>Dhanabal</surname><given-names>SP</given-names></name><name><surname>Misra</surname><given-names>VK</given-names></name><name><surname>Suja</surname><given-names>G</given-names></name></person-group>. <article-title>Antioxidant and Antimicrobial Activity of Alpinia officinarum</article-title>. <source>Indian J Pharm Sci</source> <year>2010</year>; <volume>72</volume>(<issue>1</issue>): <fpage>145</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr9-0960327111434949">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Legssyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mekhfi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bnouham</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Acute diuretic, natriuretic and hypotensive effects of a continuous perfusion of aqueous extract of <italic>Urtica dioica</italic> in the rat</article-title>. <source>J Ethnopharmacol</source> <year>2000</year>; <volume>73</volume>: <fpage>95</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr10-0960327111434949">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Testai</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chericoni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Calderone</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Nencioni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nieri</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Morelli</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiovascular effects of <italic>Urtica dioica</italic> L. (Urticaceae) roots extracts: in vitro and in vivo pharmacological studies</article-title>. <source>J Ethnopharmacol</source> <year>2002</year>; <volume>81</volume>: <fpage>105</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr11-0960327111434949">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Willer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kreher</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Biologically active compounds from the aqueous extract of <italic>Urtica dioica</italic> [in German]</article-title>. <source>Planta Med</source> <year>1989</year>; <volume>55</volume>: <fpage>452</fpage>–<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr12-0960327111434949">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huri</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Akgul</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Astarci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ustun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Germiyanoulu</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Biphasic effects of Ankaferd Blood Stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage</article-title>. <source>Saudi Med J</source> <year>2010</year>; <volume>30</volume>(<issue>8</issue>): <fpage>864</fpage>–<lpage>868</lpage>.</citation>
</ref>
<ref id="bibr13-0960327111434949">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karabıyık</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yılmaz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gülec</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haznedaroğlu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Dual diverse dynamic reversible actions of Ankaferd on EPCR and PAI-1 inside vascular endothelial cells with and without LPS</article-title>. <source>Turk J Hematol</source> <year>2011</year>. <comment>DOI:105152/tjh201141.</comment>
</citation>
</ref>
<ref id="bibr14-0960327111434949">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author"><name><surname>Kalcioglu</surname><given-names>MT</given-names></name><name><surname>Bayindir</surname><given-names>T</given-names></name><name><surname>Iraz</surname><given-names>M</given-names></name><name><surname>Kaya</surname><given-names>S</given-names></name><name><surname>Can</surname><given-names>S</given-names></name></person-group>. <article-title>The effect of a new hemostatic agent on hearing (Ankaferd Blood Stopper) in rats</article-title>. <source>J Int Adv Otol 11</source> <year>2010</year>; <volume>6</volume>: <fpage>155</fpage>–<lpage>159</lpage>.</citation></ref>
<ref id="bibr15-0960327111434949">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demiralp</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Haznedaroğlu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Functional proteomic analysis of Ankaferd<sup>®</sup> Blood Stopper</article-title>. <source>Turk J Hematol</source> <year>2010</year>; <comment>DOI:105152/tjh201139277077</comment>.</citation>
</ref>
<ref id="bibr16-0960327111434949">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author"><name><surname>Demiralp</surname><given-names>DO</given-names></name><name><surname>Haznedaroglu</surname><given-names>IC</given-names></name><name><surname>Akar</surname><given-names>N</given-names></name></person-group>. <article-title>Functional proteomic analysis of Ankaferd Blood Stopper</article-title>. <source>Turk J Hematol</source> <year>2010</year>; <volume>27</volume>: <fpage>70</fpage>–<lpage>77</lpage>.</citation></ref>
<ref id="bibr17-0960327111434949">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maralcan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kul</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baskonus</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The efficacy of Ankaferd Blood Stopper for the management of bleeding following total thyroidectomy</article-title>. <source>J Invest Surg</source> <year>2011</year>; <volume>24</volume>: <fpage>205</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr18-0960327111434949">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albayrak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aksu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Celebi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Albayrak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gınıs</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yagcı</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Striking promotion of the in vitro myeloma monoclonal immunoglobulin aggregation by Ankaferd hemostat</article-title>. <source>Inter J Hematol Oncol</source> <year>1999</year>; <volume>9</volume>: <fpage>001</fpage>–<lpage>008</lpage>.</citation>
</ref>
<ref id="bibr19-0960327111434949">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ulus</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Turan</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Ozyalçın</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aydog</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ulus</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Göker</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Surgical and histopathological effects of topical Ankaferd<sup>®</sup> hemostat on major arterial vessel injury related to elevated intra-arterial blood pressure</article-title>. <source>Turk J Hematol</source> <year>2011</year>; <volume>28</volume>: <fpage>206</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr20-0960327111434949">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ercetin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Kurt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Onal</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Aktas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kurt</surname>
<given-names>OK</given-names>
</name>
<etal/>
</person-group>. <article-title>Safety and efficacy of Ankaferd Blood Stopper in dental surgery</article-title>. <source>Inter J Hematol Oncol</source> <year>2010</year>; <volume>20</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr21-0960327111434949">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huri</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Akgul</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Astarci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ustun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Germiyanoulu</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Biphasic effects of Ankaferd Blood Stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage</article-title>. <source>Saudi Med J</source> <year>2010</year>; <volume>30</volume>(<issue>8</issue>): <fpage>864</fpage>–<lpage>868</lpage>.</citation>
</ref>
<ref id="bibr22-0960327111434949">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teker</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Korkut</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Kahya</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gedikli</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis</article-title>. <source>Eur Archiv Otorhinolaryngol</source> <year>2010</year>; <volume>267</volume>: <fpage>1377</fpage>–<lpage>1381</lpage>.</citation>
</ref>
<ref id="bibr23-0960327111434949">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelles</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kalcioglu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Samdanci</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Selimoglu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Iraz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miman</surname>
<given-names>MC</given-names>
</name>
<etal/>
</person-group>. <article-title>Ankaferd Blood Stopper is more effective than adrenaline plus lidocaine and gelatin foam in the treatment of epistaxis in rabbits</article-title>. <source>Curr Therapeutic Res</source> <year>2011</year>; <volume>72</volume>: <fpage>185</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr24-0960327111434949">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teker</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Korkut</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Gedikli</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kahya</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Prospective, controlled clinical trial of Ankaferd Blood Stopper in children undergoing tonsillectomy</article-title>. <source>Inter J Pediatr Otorhinolaryngol</source> <year>2009</year>; <volume>73</volume>: <fpage>1742</fpage>–<lpage>1745</lpage>.</citation>
</ref>
<ref id="bibr25-0960327111434949">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iynen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bozkus</surname>
<given-names>F</given-names>
</name>
<name>
<surname>San</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Alatas</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>The hemostatic efficacy of Ankaferd Blood Stopper in adenoidectomy</article-title>. <source>Int J Pediatr Otorhinolaryngol</source> <year>2011</year>; <volume>75</volume>: <fpage>1292</fpage>–<lpage>1295</lpage>.</citation>
</ref>
<ref id="bibr26-0960327111434949">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doganay</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tuncer</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ozturk</surname>
<given-names>O.</given-names>
</name>
</person-group> <article-title>Instant control of fundal variceal bleeding with a folkloric medicinal plant extract: Ankaferd Blood Stopper</article-title>. <source>Gastrointest Endosc</source> <year>2010</year>; <volume>71</volume>: <fpage>873</fpage>–<lpage>875</lpage>.</citation>
</ref>
<ref id="bibr27-0960327111434949">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Disibeyaz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Akdogan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sasmaz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Aksu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
</person-group>. <article-title>Endoscopic application of Ankaferd Blood Stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: a case report</article-title>. <source>Am J Gastroenterol</source> <year>2008</year>; <volume>103</volume>: <fpage>2156</fpage>–<lpage>2158</lpage>.</citation>
</ref>
<ref id="bibr28-0960327111434949">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kacar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Onal</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Akdogan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
</person-group>. <article-title>Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract</article-title>. <source>Endoscopy</source> <year>2008</year>; <volume>40</volume>(<issue>suppl 2</issue>): <fpage>E262</fpage>.</citation>
</ref>
<ref id="bibr29-0960327111434949">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ibis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Onal</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
</person-group>. <article-title>Successful management of bleeding due to solitary rectal ulcer via topical application of Ankaferd Blood Stopper</article-title>. <source>J Altern Complem Med</source> <year>2008</year>; <volume>14</volume>: <fpage>1073</fpage>–<lpage>1074</lpage>.</citation>
</ref>
<ref id="bibr30-0960327111434949">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Cipil</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kosar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Uz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Goker</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with Warfarin</article-title>. <source>Clin Appl Throm Hemost</source> <year>2009</year>; <volume>15</volume>: <fpage>270</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr31-0960327111434949">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mjor</surname>
<given-names>IA</given-names>
</name>
</person-group>. <article-title>Biologic assessment of restorative dental materials: interrelationship of biologic and technologic properties</article-title>. <source>Oper Dent</source> <year>1978</year>; <volume>3</volume>: <fpage>9</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr32-0960327111434949">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feigal</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Yesilsoy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Messer</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Differential sensitivity of normal human pulp and transformed mouse fibroblasts to cytotoxic challenge</article-title>. <source>Arch Oral Biol</source> <year>1985</year>; <volume>30</volume>: <fpage>609</fpage>–<lpage>613</lpage>.</citation>
</ref>
<ref id="bibr33-0960327111434949">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larche</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Changes in interferon-gamma production following specific allergen immunotherapy: biology vs methodology</article-title>. <source>Clin Exp Allergy</source> <year>2000</year>; <volume>30</volume>: <fpage>297</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr34-0960327111434949">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ercetin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<etal/>
</person-group>. <article-title>Safety and efficacy of Ankaferd Blood Stopper in dental surgery</article-title>. <source>Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi</source> <year>2010</year>; <volume>13(20)</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr35-0960327111434949">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomizawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Komori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nishida</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kurosawa</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>In vitro and in vivo evaluation of the biocompatibility and cytotoxicity of local hemostatic agents</article-title>. <source>Jpn J Cardiovasc Surg</source> <year>2004</year>; <volume>33</volume>: <fpage>382</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr36-0960327111434949">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Odabas</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Erturk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cinar</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tuzuner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tulunoglu</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Cytotoxicity of a new hemostatic agent on human pulp fibroblasts in vitro</article-title>. <source>Med Oral Patol Oral Cir Bucal</source> <year>2011</year>; <volume>16</volume>: <fpage>e584</fpage>–<lpage>e587</lpage>.</citation>
</ref>
<ref id="bibr37-0960327111434949">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author"><name><surname>Goker</surname><given-names>H</given-names></name><name><surname>Haznedaroglu</surname><given-names>IC</given-names></name><name><surname>Erçetin</surname><given-names>S</given-names></name><name><surname>Kirazlı</surname><given-names>S</given-names></name><name><surname>Akman</surname><given-names>U</given-names></name><name><surname>Ozturk</surname><given-names>Y</given-names></name><name><surname>Fırat</surname><given-names>HC</given-names></name></person-group>. <article-title>Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper</article-title>. <source>J Int Med Res</source> <year>2008</year>; <volume>36</volume>: <fpage>163</fpage>–<lpage>170</lpage>.</citation></ref>
<ref id="bibr38-0960327111434949">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jurisic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Spuzic</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Konjevic</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>A comparison of the NK cell cytotoxicity with effects of TNF-alpha against K-562 cells, determined by LDH release assay</article-title>. <source>Cancer Lett</source> <year>1999</year>; <volume>138</volume>: <fpage>67</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr39-0960327111434949">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jurisic</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Estimation of cell membrane alteration after drug treatment by LDH release</article-title>. <source>Blood</source> <year>2003</year>; <volume>101</volume>: <fpage>2894</fpage>; <comment>author reply 2895</comment>.</citation>
</ref>
<ref id="bibr40-0960327111434949">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jurisic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Konjevic</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Banicevic</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Djuricicic</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Spuzic</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Different alteration in lactate dehydrogenase activity and profile of peripheral blood mononuclear cells in Hodgkins and non-Hodgkin’s lymphomas</article-title>. <source>Eur J Haematol</source> <year>2000</year>; <volume>64</volume>: <fpage>259</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr41-0960327111434949">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jurisic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bogdanovic</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kojic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jakimov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Srdic</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Effect of TNF-alpha on Raji cells at different cellular levels estimated by various methods</article-title>. <source>Ann Hematol</source> <year>2006</year>; <volume>85</volume>: <fpage>86</fpage>–<lpage>94</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>